X
    X
    X
    X

    Lupin Pharmaceuticals Inc. and Lupin Ltd.

    A Locke Lord trial team led by Keith Parr (Chicago) represented Lupin Pharmaceuticals Inc. and Lupin Ltd. in a patent infringement case. At trial, the team argued for the U.S. District Court for the Southern District of Indiana to rule that one of Acrux DDS Pty Ltd’s patents licensed to Eli Lilly & Co. covering Axiron, a testosterone drug, is invalid, and that Lupin’s applicator would not infringe a second patent that Acrux had also licensed to Lilly. On appeal, the U. S. Court of Appeals for the Federal Circuit affirmed the judgment in its entirety. Lupin received final FDA approval for its testosterone product in late October 2017, before the Federal Circuit’s decision, clearing the way for launch of its product. The Locke Lord trial team included David Abramowitz, Carolyn Blessing and Nina Vachhani (all of Chicago). Hugh Balsam (Chicago) assisted with the appeal.
    Posted on November 30, 2017

    Explore Additional Topics

    Disclaimer

    Please understand that your communications with Locke Lord LLP through this website do not constitute or create an attorney-client relationship with Locke Lord LLP. Any information you send to Locke Lord LLP through this website is on a non-confidential and non-privileged basis. Therefore, do not send or include any information in your email that you consider to be confidential or privileged.